VBI Vaccines — Investor Presentation (September 2017)
35 slides from VBI Vaccines's investor presentation, Sep 15, 2017
Slide 1: VBI Vaccines
“> VBI VACCINES CORES ae Wy, NASDAQ: VBIV TSX: VBV : SEPTEMBER 2017
Slide 2: Cautionary Statement Regarding Forward-Looking Information
Cautionary Statement Regarding Forward-Looking Information Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 an
Slide 3: 1. Introduction to VBI Vaccines
lly, vbié 1. Introduction to VBI Vaccines RS Zam Raut NASDAQ; VBIV | TSX: VBV 3
Slide 4: VBI Vaccines Global Footprint
VBI Vaccines Global Footprint HEADQUARTERS — CAMBRIDGE, MA = CEO, CSO + 4 FTEs =" Central location in biotechnology hub RESEARCH OPERATIONS — OTTAWA, CANADA = CMO, CFO +~25 FTEs = World-class R&D team and facility MANUFACTURING FACILITY — REHOVOT, ISRAEL = ™65 FIEs = GMP manufacturing facility for t
Slide 5: VBI Vaccines Leadership
VBI Vaccines Leadership MANAGEMENT THE Jeff Boats fosk] COLUMN President & CEO GROUP GlaxoSmithKline Dr. David Anderson, Ph.D. HARVARD Chief Scientific Officer tay h Dr. Francisco Diaz-Mitoma, M.D., Ph.D. ae %, | Chief Medical Officer $ 2 * B BOARD OF DIRECTORS Dr. Steven Gillis h N) ARCHIVeaturadfi
Slide 6: Leading Immunology Innovation in Significant Markets with High Unmet Need
Leading Immunology Innovation in Significant Markets with High Unmet Need PIPELINE TECHNOLOGY PLATFORMS * Hepatitis B Vaccine: 3™ generation vaccine targeting non-responders to standard of care * Enveloped Virus-Like Particle (“eVLP”) Platform closely mimics viruses and induces potent and durable im
Slide 7: VBI Vaccines Pipeline
VBI Vaccines Pipeline Multiple Opportunities in Infectious Disease and Oncology LEAD PRE-CLINICAL PHASE | PHASE Il PHASE IIl_ APPROVED STATUS INFECTIOUS DISEASE (Hepatitis B) bcos pr alee Phill (Licensed in 15 countries) Q4 2017 Final Ph | date ted cyromessovius (cmv) [NNN = Candidate selection expe
Slide 8: Recent Key Achievements
Recent Key Achievements MAY 2016 — AUGUST 2017 August 2017 August 2017 July 2017 July 2017 June 2017 December 2016 October 2016 September 2016 July 2016 June 2016 June 2016 June 2016 May 2016 FDA Acceptance of IND and receipt of Health Canada “No Objection Letter” for Sci-B-Vac® Phase Ill clinical p
Slide 9: 2. Sci-B-Vac: Hepatitis B
ally, vbiz 2. Sci-B-Vac®: Hepatitis B NY Ss Zin Raut NASDAQ; VBIV | TSX: VBV 9
Slide 10: Hepatitis B Unmet Need
OOOO eee Hepatitis B Unmet Need Reported H is B Vaccination Coverage - 2014 Otherwise Healthy Adults aged 2 19 years 24.5% Adults aged 19-49 years 32.2% Adults age 2 50 years 15.7% High-Risk Chronic Liver Conditions 29.8% Diabetics — Age 19-59 years 23.5% Diabetics — Age > 60 years 13.5% Healthcare
Slide 11: Existing High Unmet Need in Specific Populations
OOOO eee Existing High Unmet Need in Specific Populations SEROCONVERSION RATES WITH CURRENT VACCINES FALL DRAMATICALLY WITHIN THE ELDERLY AND HIGH-RISK PATIENT POPULATIONS Anti-HBs Seroconversion Rates After Hepatitis B Vaccination Neonates >95% Age 2-19 ~99% Age 20-29 ~95% Age 30 - 39 ~90% Age 40 -
Slide 12: Sci-B-Vac Overview
Sci-B-Vac® Overview ONLY COMMERCIAL HBV VACCINE KNOWN TO MIMIC ALL THREE VIRAL SURFACE ANTIGENS — ALREADY SAFELY USED IN 300,000+ PATIENTS * Sci-B-Vac® achieves rapid onset of protection, with high levels of anti-HBV antibodies (HBsAb), at a lower dosage than competing vaccines 2D GENERATION VACCINE
Slide 13: Sci-B-Vac Existing Safety and Efficacy Data Package
OOOO eee Sci-B-Vac® Existing Safety and Efficacy Data Package EXTENSIVE CLINICAL DEVELOPMENT SUPPORTS PHASE III DESIGN * Product distribution data globally estimates that over 300,000 infants and adults have been vaccinated with Sci-B-Vac® * Inthe last two decades, 22 clinical trials have been compl
Slide 14: Sci-B-Vac Demonstrated Superior Seroprotection Rates in Older Adults
Sci-B-Vac® Demonstrated Superior Seroprotection Rates in Older Adults Stratification by Age of Study 38-96-040 Demonstrates Significantly Improved Potency in Older Adults Seroprotection Stratified by Age 100.0% z g 95.0% Yy B 90.0% | 86.0% 5 85.0% Ly pee Yy 4 78.3% Yy 3 75.0% y 1 70.0% Gs 2 65.0% Ye
Slide 15: Interim Data from Israeli Phase IV Study Reinforces Sci-B-Vac Potency
Interim Data from Israeli Phase IV Study Reinforces Strength of Sci- B-Vac® Potency in Adult Populations & Potential for Rapid Seroprotection SCI-B-VAC® PHASE IV STUDY IN ISRAELI ADULTS (AGE 18-40, N=88) SEROPROTECTION (>10 IU/ML) 100% 5 98.8% 20% 91.9% 60% 56.8% 40% 20% 0% 1 (P1Vd30) 2 (P2vd30) 3 (
Slide 16: Proposed Phase III Clinical Program
OOOO eee Proposed Phase III Clinical Program BASED ON DISCUSSIONS WITH AND FEEDBACK FROM THE FDA, EMA, AND HEALTH CANADA IN H1 2017, THE PROPOSED PHASE III DESIGN IS: @ Target Population: ~4,800 adults age 18 years and older Expected Duration: 15 Months Clinical Trial Sites: “40 sites across the US,
Slide 17: 3. eVLP Portfolio Programs
ON, BZ 3. eVLP Portfolio Programs S Ms Raut NASDAQ; VBIV | TSX: VBV 7
Slide 18: eVLPs are a 3rd-Generation Class of Synthetic Vaccines
OOOO eee eVLPs are a 3'-Generation Class of Synthetic Vaccines = eVLPs are the same size and structure as enveloped viruses; present antigens in their natural state for an improved immune response = The foundation of the eVLP Platform is a stable, protein-based core on which additional vaccine antig
Slide 19: 3. eVLP Portfolio Programs: a. CMV
3. eVLP Portfolio Programs a. CMV NASDAQ: VBIV | TSX: VBV 19
Slide 20: Congenital CMV is a Leading Public Health Priority
Congenital CMV is a Leading Public Health Priority U.S. CHILDREN BORN WITH OR DEVELOPING LONG-TERM MEDICAL CONDITIONS Congenital CMV Disease Fetal Alcohol Syndrore | as Down Syndrome Spina Bifida / Anencephaly CMV affects more live births than Down Syndrome or Fetal Alcohol Syndrome Pediatric HIV/AI
Slide 21: Congenital CMV is a Leading Public Health Priority
OOOO eee Congenital CMV is a Leading Public Health Priority = Each year, approximately 30,000 infants are born each year with CMV infection, of which 5,000+ U.S. infants will develop permanent problems including deafness, blindness, and developmental delays = Inthe U.S., the direct economic costs of
Slide 22: eVLP Presentation Improves CMV Vaccine Potency
eVLP Presentation Improves CMV Vaccine Potency Presentation of gB antigen in an eVLP improves relevant functional CMV neutralizing responses relative to recombinant gB protein PRECLINICAL RESULTS Neutralizing antibody titers for mice immunized 1, Bs f 7 with comparable doses of Recombinant gB of ¢ N
Slide 23: CMV Phase I Clinical Trial Overview
CMV Phase | Clinical Trial Overview Opportunity for Immunologic Human Proof of Concept with Ph | Data TRIAL DESIGN Target Population: 125 CMV-Negative Healthy Adults (18-40 yrs) ¢ Design: Staggered Enrollment with Vaccinations at 0, 2, and 6 Months ¢ Expected Duration: 20 Months * Interim Data Read-
Slide 24: Interim Phase I Immunogenicity Signals (1)
Interim Phase | Immunogenicity Signals (1) BASED ON SUBJECT SAMPLES COLLECTED 1 MONTH AFTER 2ND VACCINATION After two vaccinations, immunization of subjects with the highest dose of VBI-1501A (2.0ug) induced: * Seroconversion* in 100% of subjects ¢ Adjuvant (alum) enhances immunogenicity * Neutraliz
Slide 25: Interim Phase I Immunogenicity Signals (2)
Interim Phase | Immunogenicity Signals (2) BASED ON SUBJECT SAMPLES COLLECTED 1 MONTH AFTER 2ND VACCINATION Clear dose-dependent boosting of response: 25 20: Fold-increase is based on comparison of antibody binding GMTs at day 56 (post 1% vaccination) vs. Fold-increase a 10: day 84 (1 month post 2"4
Slide 26: Interim Phase I Data Summary
OOOO eee Interim Phase | Data Summary ¢ VBI-1501A is safe and well tolerated at all doses tested ¢ VBI-1501A is immunogenic after 2 doses o Evidence of strong boosting in antibody titers observed, which is dose-dependent Observed neutralizing antibodies against epithelial cell infection in some subj
Slide 27: 3. eVLP Portfolio Programs: b. GBM
3. eVLP Portfolio Programs b. GBM NASDAQ: VBIV | TSX: VBV 27
Slide 28: Therapeutic GBM Candidate Builds on Prophylactic CMV Candidate
Therapeutic GBM Candidate Builds on Prophylactic CMV Candidate (VBI-1501A) by Adding an Internal pp65 Protein to Elicit a Th1 Response Attributes gB Envelope pp65 v ‘NeoAntigen’ Vv ‘NeoAntigen’ Bivalent — pp65 for Therapeutic Immuno- Oncology Monovalent gB for Prophylaxis Present antigen in natural
Slide 29: Poor Immunogenicity of Traditional Tumor-Associated Antigens
Poor Immunogenicity of Traditional Tumor-Associated Antigens (TAAs) has Limited Past Therapeutic Cancer Vaccines IMMUNOGENICITY LOW —————————— “IG VIRAL CMV ANTIGENS ARE OVER-EXPRESSED (>90%) IN MULTIPLE SOLID TUMORS, INCLUDING: * Glioblastoma (GBM)! ¢ Medulloblastoma?? * Meningioma? * Breast cance
Slide 30: VBI-1901: Re-stimulated CD4+ and CD8+ T-cell Responses
VBI-1901: Re-stimulated CD4+ and CD8+ T-cell Responses in CMV-positive Human Subject Ex Vivo Restimulation of CD4+ & CD8+ T-cells in ¢ Fresh PBMCs stimulated Ex Vivo Human Samples with VBI-1901 vs iS CD4*IFN-y* CD8*IFN-* recombinant antigens 9 25 c * eVLPs rapidly restimulate a 2.0 2 both CD4+ & CD8
Slide 31: VBI-1901 Induction of CCL3 in Ex Vivo PBMCs
VBI-1901 Induction of CCL3 in Ex Vivo PBMCs from CMV-positive Healthy Subjects and Patients with Solid Tumors = = CCL3 Secretion E 105 a a2 45 a co = an °o on g S af 10 2 “Fs 3 38 2 $c 5 3 2s 8 : ge Sy ne 0: & x ~) ~ g¥ & & s fo) * PBMCs from CMV+ healthy subjects or patients with GBM, medulloblasto
Slide 32: VBI GBM Candidate Expected Timeline
OOOO eee VBI GBM Candidate Expected Timeline COMPLETED MILESTONES v Q1 2016: Pre-clinical IND-enabling data Y Q12016: Clinical Advisory Meeting v Q2 2016: Pre-IND meeting with FDA v Q1 2017: GMP clinical trial materials manufactured Y Q3 2017: IND accepted for Phase I/Ila clinical study REMAINING MI
Slide 33: 4. Summary
4. Summary Raut NASDAQ; VBIV | TSX: VBV 33
Slide 34: Value Proposition for VBI Vaccines
NAN Value Proposition for VBI Vaccines KEY VALUE DRIVERS IN NEXT 12 MONTHS: Sci-B-Vac®: Phase III Program in the U.S., Europe, and Canada Initiation of enrollment in Q4 2017, results expected H1 2019 @ CMV: Phase | Clinical Study Final results expected H1 2018 GBM: Phase I/Ila Clinical Study Initiat
Slide 35: VBI Vaccines Inc.
VBI Vaccines Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 info@vbivaccines.com AQ: VBIV | TSX: VBV
VBI Vaccines — Investor Presentation (September 2017) on 6ix